OncoViews
  • Therapy Areas
  • Latest
  • CHECK-IN NOW
Advancing Frontline Treatment: Managing Enfortumab Vedotin and Pembrolizumab Toxicities in Metastatic Urothelial Cancer

Advancing Frontline Treatment: Managing Enfortumab Vedotin and Pembrolizumab Toxicities in Metastatic Urothelial Cancer

by Terence Friedlander | 27 March 2025 | Antibody Drug Conjugates, Urogenital

Dr. Terence Friedlander, a medical oncologist and professor of medicine at the University of California, San Francisco, recently discussed key insights from clinical practice regarding the combination of enfortumab vedotin (EV) and pembrolizumab in patients with...
Breaking Down the Complexities of Non-Clear Cell RCC Entities

Breaking Down the Complexities of Non-Clear Cell RCC Entities

by Viktor Grünwald | 18 November 2024 | Urogenital

In recent years, the field of kidney cancer has seen significant advancements, especially regarding treatment options for rarer subtypes beyond the more common clear cell renal cell carcinoma (ccRCC). Dr. Victor Grünwald, a medical oncologist specialising in...
European Commission Approves New Treatments for Urothelial and Lung Cancer

European Commission Approves New Treatments for Urothelial and Lung Cancer

by EMA Approval | 30 August 2024 | Lung Cancer, Urogenital

The European Commission has approved two new cancer treatments: enfortumab vedotin in combination with pembrolizumab for urothelial cancer and amivantamab-vmjw in combination with chemotherapy for non-small cell lung cancer (NSCLC). These approvals mark significant...
EU Recommends New Treatments for Endometrial and Urothelial Cancers

EU Recommends New Treatments for Endometrial and Urothelial Cancers

by EMA Approval | 12 July 2024 | Urogenital, Women's Cancers

The European Union has recommended new treatment options for patients with primary advanced or recurrent endometrial cancer and metastatic urothelial carcinoma. Durvalumab and Olaparib have been endorsed for endometrial cancer based on positive trial results, while...
Metastatic Prostate Cancer: Optimization of Systemic Treatment

Metastatic Prostate Cancer: Optimization of Systemic Treatment

by Deborah Mukherji | 3 July 2024 | Urogenital

Clinical trials investigating various drugs in patients with metastatic hormone-sensitive or castration-resistant prostate cancer have revealed significant benefits. While research is ongoing to shed light on issues such as sequencing, treatment de-escalation and...
Recent Advances in Cancer Treatment: New Approvals in Prostate, Solid Tumors, and Colorectal Cancer

Recent Advances in Cancer Treatment: New Approvals in Prostate, Solid Tumors, and Colorectal Cancer

by Swiss Approval | 24 June 2024 | Urogenital

In recent developments within the field of oncology, several new treatment options have received approval, offering fresh hope for patients battling various forms of cancer. These approvals highlight the advancements in targeted therapies and the ongoing commitment to...
« Older Entries

Recent Posts

  • Antibody-Drug Conjugates in Breast Cancer: Advancing Precision Treatment
  • Diagnosis of Lung Cancer: Biomarker Testing on the Road to the Future
  • Advancing Frontline Treatment: Managing Enfortumab Vedotin and Pembrolizumab Toxicities in Metastatic Urothelial Cancer
  • Endometrial Cancer: A Revolution That Is Only Just Beginning
  • Advanced Ovarian Cancer: In Search of the Ideal Strategy

Recent Comments

No comments to show.

Share your patient case for discussion

Let our faculty discuss your patient case during the roundtables - rest assured, we'll keep you posted!

submit patient case

Quick Links

Twitter
LinkedIn
Contact
Terms Of Use
Privacy Policy
Legal Notice

Our Partners

Leading Opinions

Choose your area of interest

Join our network and become an OncoViewer!

SIGN UP FOR FREE
Lung Icon

Lung Cancer

NSCLC, Mesothelioma, SCLC
Uterus Icon

Women's Cancers

Breast Cancer, Gynecologic Cancers
GI Icon

Gastrointestinal

Upper & Lower GI, Pancreatic, HCC
Bladder Icon

Urogenital

Renal, Urothelial & Prostate
Hematology Icon

Hematology

Hodgkin- & Non-Hodgkin Lymphomas
Other Solid Tumor Icon

Other Solid Tumors

Melanoma, Head & Neck Cancer, etc

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}